Kokoschka E M
Hautarzt. 1979 Dec;30(12):656-61.
Principles, possibilities and limits of an immunotherapy of malignant melanoma are discussed. On account of the results of immunological investigations in melanoma patients and in animal models the immunogenicity of melanoma cells and the stage dependent immune reactivity of tumor bears seem to be certain. These facts have been the rational basis for the evaluation of an immunotherapy in malignant melanoma. Netherless these therapy trials are still in the state of clinical testing. Controlled long term studies of immunotherapy schedules under observation of the immune profile of the patients in vivo and in vitro are necessary in order to determine the place of immunotherapy within the range of oncological therapeutic possibilities.
本文讨论了恶性黑色素瘤免疫治疗的原理、可能性和局限性。基于对黑色素瘤患者和动物模型的免疫学研究结果,黑色素瘤细胞的免疫原性以及肿瘤宿主的阶段依赖性免疫反应性似乎是确定的。这些事实是评估恶性黑色素瘤免疫治疗的合理依据。然而,这些治疗试验仍处于临床试验阶段。为了确定免疫治疗在肿瘤治疗可能性范围内的地位,有必要在体内和体外观察患者免疫状况的情况下,对免疫治疗方案进行长期对照研究。